Pharmacology articles

Los artículos más importantes de 2018 en farmacología / cardiología clínica - 2° parte

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology – Part 2

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology – Part 2

1- What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more    2- New European Hypertension Guidelines Contrast with American Recommendations The European

¿La epidemia de obesidad pone en riesgo la salud de los pacientes y los médicos?

Is the Obesity Epidemic Putting Patients’ and Physicians’ Health at Risk?

Is the Obesity Epidemic Putting Patients’ and Physicians’ Health at Risk? In addition to the obvious negative effect on patients, obesity can also affect Interventional Cardiologists’ health, seeing as it involves increased exposure to radiation.   Operators are clearly and increasingly exposed to radiation as patient body mass index (BMI) increases. Radiation exposure might be

La ATC es una alternativa válida en el TCI

Left Main PCI Technique Could Change DAPT Duration

Up to 20% of patients undergoing left main PCI require a 2-stent technique, and this number should most likely grow after the DKCRUSH-V outcomes. However, this study contradicts the DKCRUSH-V and brings us back to “the simpler the better”, since patients undergoing 1 stent left main PCI presented less revascularization and less target vessel failure

Lo más leído de 2018 en solaci.org

The 10 most consulted articles at SOLACI during 2018

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more    2- The 10 Commandments of ESC’s New STEMI Guidelines The authors

ticagrelor vs clopidogrel en enfermedad vascular periferica

What is the best antiplatelet in PCI to vein grafts?

Courtesy of Dr. Carlos Fava. PCI to saphenous vein grafts is one the greatest challenges these days because, as opposed to native arteries, they present important thrombolytic material, diffuse and long lesions, and abundant macrophage and inflammatory cells, which makes the procedure more complex. At present, we have not yet agreed on the best antiplatelet

masleidodiciembre

The 10 Most Read Articles of December

1- Everolimus-Eluting Stents Finally Have a Rival and Not Just a “Non-Inferior” Stent In this large randomized trial, there were significant differences as regards both target-lesion failure and target-vessel-related infarction, which persisted through a 2-year follow-up and favored treatment with an ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (Orsiro) compared with the gold standard, a durable-polymer everolimus-eluting stent

cigarrillos-electronicos-web-compressor

E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution

E-cigarettes may bring about cardiac risk according to a new literature review soon to be published in J Am Coll Cardiol. The evidence on potential harm is not definitive, but some experts suggest caution in their use until there is more solid evidence. E-cigarettes have been advertised as a healthy alternative to traditional cigarettes and

Es posible suspender los Betabloqueantes post infarto agudo de miocardio

Can We Discontinue Betablockers after AMI?

Betablockers (BB) were the first drugs shown to effectively reduce events after acute MI. However, reperfusion and other secondary prevention drugs that came along after that have cast a shadow on betablockers’ original benefit. This study looked at betablocker discontinuation after acute MI in patients with no cardiac failure optimally treated with all recommended medication.

Sub análisis del EXCEL: angioplastia vs cirugía en insuficiencia renal crónica

Strategies to Reduce Acute Kidney Injury in Angioplasty

The title of this article leads us to think that we will find a list of things that we can do to reduce kidney injury. However, (unfortunately) sodium bicarbonate showed no benefit over saline and n-acetylcysteine showed no benefit over a placebo for the reduction of kidney damage after coronary angioplasty. Among the protective measures

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

Aspirin, Bleeding and Cardiovascular Events in Healthy Elderly

The ASCEND and ARRIVE trials -presented at the European Cardiology Congress and published in The New England Journal of Medicine (NEJM) and The Lancet respectively- have put against the ropes the indication of aspirin in the context of primary prevention. The ASPREE trial, recently published in the NEJM, appears to have definitely overthrown aspirin, since

Top